This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
Pivotal Trial Results
Post-Hoc Analysis Results
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Example of description text sitting alongside header
Example of description text sitting alongside header
Example of description text sitting alongside header
JADE MONO-1 and MONO-2 evaluated efficacy and safety endpoints up to 12 weeks in two identically designed double-blind, placebo-controlled clinical trials in which 778 patients aged 12 and older with moderate-to-severe AD received CIBINQO 100 mg, CIBINQO 200 mg, or placebo.1,2
Differences in the PP-NRS average change from baseline between both doses of CIBINQO and placebo were observed through week 12, starting within 24 hours of the first dose.
RECOMMENDED DOSE: CIBINQO 100 mg
If response to 100 mg is inadequate, consider increasing to 200 mg. Discontinue if inadequate response is seen after dose increase.
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2024 Pfizer Inc. All rights reserved.